SCHEMBL3138385

SCHEMBL3138385

Cc1cc(F)ccc1Br.[MgH2]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
ACHE P22303 2/20 0.38
MAPT P10636 4/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
KMT2A Q03164 1/20 0.37
RELA Q04206 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HDAC4 P56524 1/20 0.35
HAO1 Q9UJM8 1/20 0.33
CHRNA1 P02708 1/20 0.33
CHRNG P07510 1/20 0.33
CHRNB1 P11230 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL306113 0.97
SCHEMBL29421562 0.97
Ammonia Solution, Strong SCHEMBL28164484 0.95 ALDH1A1 (0.40) ALDH1A1ACHEMAPTNPC1RAB9A
Fluoride SCHEMBL27656662 0.95 ALDH1A1 (0.40) ALDH1A1ACHEMAPTNPC1RAB9A
Cyanide SCHEMBL28824673 0.91 ALDH1A1 (0.37) ALDH1A1ACHEMAPTNPC1RAB9A
Formic Acid SCHEMBL28032861 0.85 ALDH1A1 (0.39) ALDH1A1MAPTNPC1RAB9AMEN1
SCHEMBL1492581 0.80 ALDH1A1 (0.40) ALDH1A1ACHEMAPTNPC1RAB9A
SCHEMBL22778153 0.79 TNKS2 (0.43) ALDH1A1ACHEMAPTNPC1RAB9A
SCHEMBL29468034 0.79 TNKS2 (0.43) ALDH1A1ACHEMAPTNPC1RAB9A
SCHEMBL257139 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117976986-A Fluorine-containing rechargeable magnesium battery electrolyte and preparation method and application thereof 重庆大学 2024-05-03 CN disclosed
CN-112955436-B 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines 福建盛迪医药有限公司 2023-08-11 CN disclosed
CN-110177554-B Combination therapy for the treatment of cancer G1治疗公司 2023-06-02 CN disclosed
CN-112996774-B 2-oxo-1,2-dihydropyridine derivative, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2022-11-22 CN disclosed
CN-108699024-B Benzothienyl selective estrogen receptor down-regulator compounds 伊利诺伊大学评议会 2022-03-11 CN disclosed
CN-108495628-B Benzothienyl selective estrogen receptor down-modulators 伊利诺伊大学评议会 2022-01-11 CN disclosed
CN-112996774-A 2-oxo-1, 2-dihydropyridine derivatives, preparation method and application thereof in medicines 江苏恒瑞医药股份有限公司 2021-06-18 CN disclosed
CN-112955436-A 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines 江苏恒瑞医药股份有限公司 2021-06-11 CN disclosed
US-10858366-B2 Tricyclic compounds useful to treat orthomyxovirus infections NOVARTIS AG (CH) 2020-12-08 US disclosed
WO-2020140959-A1 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2020-07-09 WO disclosed
EP-1326832-B1 CHEMICAL COMPOUNDS GLAXO GROUP LTD (GB) 2004-10-06 EP disclosed
US-20040127485-A1 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists GLAXO GROUP LIMITED (GB) 2004-07-01 US disclosed
US-20040014770-A1 Chemical compounds GLAXO GROUP LIMITED (GB) 2004-01-22 US disclosed
EP-1377558-A1 [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-01-07 EP disclosed
WO-2003066635-A1 PIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-08-14 WO disclosed
WO-2003066621-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS GLAXO GROUP LIMITED (GB) 2003-08-14 WO disclosed
WO-2003066589-A1 PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2003-08-14 WO disclosed
EP-1326832-A1 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2003-07-16 EP disclosed
WO-2002081457-A1 `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS GLAXO GROUP LIMITED (GB) 2002-10-17 WO disclosed
WO-2002032867-A1 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858366-B2 Tricyclic compounds useful to treat orthomyxovirus infections ZC3HAV1, OTC, THOP1 ALDH1A1 4445/4885ACHE 320/4885MAPT 797/4885
US-20040127485-A1 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists NPY1R, CRHR1, GRIN1 ALDH1A1 2441/4885ACHE 2007/4885MAPT 3460/4885
US-20040014770-A1 Chemical compounds HCK, KCNK4, GRK4 ALDH1A1 2296/4885ACHE 2734/4885MAPT 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.